Compare NOA & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOA | LCTX |
|---|---|---|
| Founded | 1953 | 1990 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Meat/Poultry/Fish | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 349.9M | 301.7M |
| IPO Year | 2006 | 1996 |
| Metric | NOA | LCTX |
|---|---|---|
| Price | $13.41 | $1.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 56.5K | ★ 906.7K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,556,000.00 |
| Revenue This Year | $14.77 | $109.40 |
| Revenue Next Year | $5.43 | N/A |
| P/E Ratio | $18.05 | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $12.07 | $1.00 |
| 52 Week High | $17.26 | $2.09 |
| Indicator | NOA | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.11 | 44.84 |
| Support Level | $12.97 | $1.00 |
| Resistance Level | $14.51 | $1.18 |
| Average True Range (ATR) | 0.61 | 0.05 |
| MACD | -0.11 | 0.00 |
| Stochastic Oscillator | 2.52 | 32.14 |
North American Construction Group Ltd is Canada's heavy civil construction and mining contractor provider. The company has provided services to oil, natural gas, and resource companies. The Company provides a wide range of mining and heavy civil construction services to customer in the resource development and industrial construction sectors within Canada, the United States, and Australia. The Company's reportable segments are Heavy Equipment Canada, Heavy Equipment Australia, and Other. Heavy Equipment Canada and Heavy Equipment Australia include all of aspects of the mining and heavy civil construction services provided within those geographic areas. Other includes mine management contract work in the United States, its external maintenance and rebuild programs.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.